Binders Excipients - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The binders excipients market size is expected to increase from USD 1.48 billion in 2025 to USD 1.55 billion in 2026 and reach USD 1.94 billion by 2031, growing at a CAGR of 4.58% over 2026-2031. This report is segmented by Source (Natural, Synthetic, and Semi-Synthetic Binders), Application (Tablets, Capsules, Solution-Based, and Modified-Release and Taste-Masked Formulations), End User (Pharmaceutical Companies, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Binders Excipients Market Trends and Insights

Growth of Generic and Biosimilar Oral Solid Dose Manufacturing

Generic oral solid dosage forms remain the primary volume driver for binders, with the patent expiry cycle continuing to support demand. The FDA’s generic drug program is expected to process more than 35,000 cumulative ANDA approvals through 2025. The growing number of biosimilar approvals also supports future formulation activity, although binder requirements vary by dosage form. Large-scale manufacturing programs favor grades that deliver stable granules and consistent compression performance. The binders excipients market benefits as generic manufacturers expand tablet and capsule production across multiple therapeutic areas. Binder qualification is increasingly shifting to CDMOs, which manage development and manufacturing for multiple customers, rather than remaining solely at originator sites. Suppliers that pre-qualify grades for standard generic platforms and maintain current regulatory files across multiple jurisdictions are better positioned to secure repeat orders.

Demand for Multifunctional and Co-processed Excipients

Co-processed excipients provide binding, filling, and disintegration functions within direct-compression workflows. A 2025 study found that co-processed excipients improved flowability, compressibility, and disintegration performance compared with physical blends of their individual components. These attributes are increasingly important for tablet manufacturers operating high-speed presses and seeking to streamline formulation processes. The existing pharmacopoeial status of the underlying materials can also simplify the development pathway compared with introducing a new chemical entity. Evonik is expected to receive a Market Impact Award at CPHI China 2026 for its EUDRAGIT polymer platform, underscoring the commercial value of functional polymer systems. The binders excipients market is moving toward suppliers that combine co-processing capabilities with formulation support. Commodity suppliers offering only starch or PVP grades face increasing challenges as customers seek integrated performance solutions.

Complex and Regionally Variable Excipient Regulation

The absence of a harmonized global regulatory framework for excipients creates ongoing compliance challenges for suppliers and formulators. In the United States, excipients are reviewed as part of the finished drug application, with Type IV Drug Master Files serving as a standard documentation pathway. In the European Union, the European Medicines Agency’s (EMA) draft guideline defines excipient requirements for marketing authorization dossiers. China follows a national standards system that does not fully align with the United States Pharmacopeia-National Formulary (USP-NF) and European Pharmacopeia monographs. The EMA is expected to update its excipient labeling annex guidance in 2025, while the World Health Organization (WHO) issued good manufacturing practice (GMP) guidance for excipient manufacturers in 2024. These differing regulatory requirements increase compliance costs for participants in the binders and excipients market, particularly due to the need for multi-compendial compliance and variation filings. The burden is more pronounced for smaller regional suppliers, while established suppliers benefit from their ability to support global customers and retain key accounts.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Pharmaceutical and Nutraceutical Production in the Asia-Pacific
• Continuous Manufacturing and High-Shear Granulation Adoption
• High Qualification and Change-Control Costs

Segment Analysis

Natural binders are expected to account for 57.65% of the binders excipients market share in 2025. Their leading position is supported by established pharmacopoeial status, broad regulatory acceptance, and lower qualification requirements than many synthetic alternatives. Microcrystalline cellulose, hydroxypropyl methylcellulose, starch, and guar gum are expected to account for a significant share of natural binder use in tablet manufacturing. Gelatin will remain relevant for selected tablet formats and modified-release capsule fills. Semi-synthetic materials offer a balance between familiar source materials and more controlled functional performance.

Synthetic binders are projected to be the fastest-growing source category, with a forecast CAGR of 6.5% from 2026 to 2031. PVP and copovidone offer tighter viscosity control, greater batch consistency, and compatibility with twin-screw granulation. A 2025 study is expected to demonstrate that viscosity and surface tension influence granule growth and tablet tensile strength during high-shear wet granulation. The EU restriction on synthetic polymeric microplastics will introduce reporting obligations for materials within its scope from May 2027. As a result, the source mix within the binders excipients market will be influenced by both processing performance and evolving compliance requirements.

Complete Report Scope:

• By Source
  • Natural Binders
    • Plant-derived Binders
    • Animal-derived Binders
  • Synthetic Binders
  • Semi-synthetic Binders
• By Application
  • Tablets
  • Capsules
  • Solution-based Formulations
  • Modified-release and Taste-masked Formulations
• By End User
  • Pharmaceutical Companies
  • Nutraceutical Companies
  • Contract Manufacturing and Development Organizations
  • Biotechnology Companies
  • Research and Development Laboratories
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America is expected to account for 43.65% of the binders excipients market size in 2025. Large generic drug operations, FDA-centered regulation, and GMP manufacturing facilities underpin the region’s position in the binders and excipients market. GDUFA IV will take effect in 2028 and introduce pre-submission meeting types for complex generic drug applicants. The National Supply Chain Resilience Act will require domestic or allied-nation sourcing for 50% of APIs used in Medicare and Medicaid drugs by 2030. BASF will open a GMP Solution Center in Wyandotte, Michigan, in June 2025, while Canada and Mexico will contribute additional demand.

Europe will maintain a significant position in the binders excipients market, led by Germany, France, and the United Kingdom. These countries have established pharmaceutical manufacturers and generic drug producers that use cellulose, starch, and polymer binders. Germany benefits from local supply networks that include Evonik, BASF, and MEGGLE. Evonik and Higuchi will open the Open Pharma Lab in Yokohama in April 2026, extending European technical support into Asia. European suppliers will manage compliance costs associated with REACH and EMA labeling guidance, while Brazil will lead demand in South America.

Asia-Pacific is forecast to grow at a CAGR of 5.7% from 2026 to 2031, representing the fastest growth rate in the binders excipients market. India supplies more than 20% of global generic drug volumes and requires reliable GMP-grade binders. India’s QR code requirement, scheduled for March 2026, will formalize excipient identity documentation, while Chinese producers are increasing the supply of locally certified binders. The Middle East and Africa will remain smaller but active markets as Saudi Arabia, the UAE, and South Africa expand pharmaceutical manufacturing capacity.

List of Companies Covered in this Report:

• Ashland
• Archer Daniels Midland Company
• BENEO GmbH
• Croda International Plc
• Colorcon, Inc.
• DFE Pharma GmbH & Co. KG
• Evonik Industries
• Fuji Chemical Industries Co., Ltd.
• Ingredion Incorporated
• JRS Pharma GmbH & Co. KG
• Kerry Group plc
• Merck
• Roquette Frères
• Scope Ingredients Pvt. Ltd.
• Shin-Etsu Chemical Co., Ltd.
• Lubrizol

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support